StageAcq - P2P | Acquired
Missing: Ventritex's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ventritex's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Ventritex News
Feb 5, 2014
St. Jude to Purchase Ventritex, Other Units for $660 Million Acquisitions: Moves are part of a plan to expand its market beyond heart valves. October 24, 1996 |From Times Wire Services St. Jude Medical Inc. will pay about $660 million in stock and cash for Ventritex Inc. of Sunnyvale, Calif., and other acquisitions, expanding its share of the market for devices that treat irregular heartbeats. 1 maker of mechanical heart valves, will pay about $505 million in stock for Ventritex, a maker of defibrillators, which slow a patient's heartbeat. The St. Paul, Minn.-based company will also acquire Pacific Dunlop Ltd.'s Teletronics and Medtel units for $130 million in cash and pay $25 million for intellectual property rights from Sulzer's Intermedics. The moves, which put St. Jude in a market with an annual growth rate of 20% to 25%, are part of its plan to expand beyond heart valves--a maturing business that still generates lots of cash. "St. Jude will have its hands full trying to make this work," said Michael Weinstein, a J.P. Morgan Securities analyst. "Assuming they can, it will raise the company's long-term growth rate. " In the Ventritex acquisition, that company's stockholders will receive 0.6 share of St. Jude Medical for each of their shares. The ratio isn't dependent on St. Jude's stock price. The transaction values Ventritex at $505 million based on Tuesday's closing prices. Ventritex will purchase as many as 200,000 of its own shares before the transaction closes, which is expected later this year or in early 1997. President and Chief Executive Frank Fischer will remain with the company. Ventritex shares rose .9375 to $21.5625 on Nasdaq. St. Jude fell $1.25 to $37.375, also on Nasdaq. Ventritex has lost the technological lead it once had in the defibrillator market. Rivals Medtronic and Guidant Corp. beat it to market with defibrillators small enough to be implanted on the chest instead of the abdomen. Such implants reduce the time needed for surgery to implant the device as well as recovery time. Both Medtronic and Guidant have gained market share at Ventritex's expense as a result. To be sure, St. Jude's acquisition of Ventritex could change that trend, analysts said. "This will make Ventritex a more powerful contender," said Rachael Scherer, a Dain Bosworth analyst. Analysts said they expect the acquisition to dilute St. Jude's earnings next year and possibly in 1998. The company declined to comment on any earnings impact. "The magnitude depends on how fast things happen," said Steve Wilson, St. Jude's chief financial officer. "Both Ventritex and Teletronics are losing money but are well-positioned and poised to do better. The question is how far they bounce back and how soon. " Teletronics ran into problems last year, when two types of pacemaker wires broke inside the chests of several heart patients, prompting several lawsuits. In its purchase, St. Jude didn't take on the legal liabilities associated with those lead wires. Teletronics is close to getting government approval for several new pacemaker products that are based on a different type of sensor than existing Pacesetter products, St. Jude's Wilson said. The products are rate-responsive, which would allow a heart patient to exercise and briefly raise his heart rate without prompting a response from the pacemaker. The Teletronics agreement also includes a provision for additional payments of as much as $40 million to Pacific Dunlop over six years if certain sales milestones are met. St. Jude will also acquire some intellectual property rights from Intermedics Inc., a Freeport, Texas, unit of SulzerMedica Inc., for $25 million. That agreement includes the settlement of disputes between Intermedics and Ventritex. Wilson said the company is confident that the agreements mean St. Jude won't be sued by Medtronic or Guidant for patent violations. "The intellectual property was key," he said. "We have taken steps to ensure we will be in all markets. " FEATURED
Ventritex Frequently Asked Questions (FAQ)
Where is Ventritex's headquarters?
Ventritex's headquarters is located at 10065 Red Run Blvd., Minneapolis.
What is Ventritex's latest funding round?
Ventritex's latest funding round is Acq - P2P.
Who are the investors of Ventritex?
Investors of Ventritex include St. Jude Medical, U.S. Venture Partners, InterWest Partners, MedVenture Associates, Sanderling Ventures and 4 more.
Who are Ventritex's competitors?
Competitors of Ventritex include Spineology, Vertos Medical, Endotronix, NinePoint Medical, Coherex Medical and 13 more.
Compare Ventritex to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Urovalve, Inc. has developed and patented technology to control fluid flow through small diameter flexible tubing. The core technology for the Surinate bladder management system is comprised of a magnetically controlled valve that can be activated remotely by a Surinate wearer who uses a hand held magnet to self-regulate flow. Currently available devices require continuous bladder drainage or insertion of a tube into the urethra several times each day. The Surinate bladder management system aims to provide a solution to the problems of life style, urinary tract infections, and substantial healthcare worker expenses associated with existing catheters.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
MST - Medical Smart Tools was founded in 2004 with the mission to develop image guided surgery technology solutions. The Company aims to improve laparoscopic and other minimally invasive surgical procedures and medical staff effectiveness, thus increasing hospital efficiencies, reducing surgical costs, and improving patient outcomes. MST is working within NGT, a private technological incubator in Nazareth, Israel. MST presents the market with a smart disposable Robotic Arm camera holder for laparoscopy, based on advanced image technology. The system is comprised of a computer-controlled mechanism for mechanical camera motivation, intuitive interface between the surgeon and the mechanical system. The company's R&D efforts are spearheaded by a core group of engineers with expertise in image processing, dynamics of mechanisms, multi-link systems and biomechanics. The Company is backed by strong and experienced management and professional medical advisors.
Percutaneous Systems is a medical device company. It had developed the Accordion Stone Management Device Model Ac281205 And Ac3814510.
Developing minimally invasive methods and devices for treating congestive failure and cardiac valve diseasen(Acquired by ev3)
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.